Lupin Receives Health Canada Approval for Biosimilar Pegfilgrastim
Overview
Global pharma major Lupin Limited (Lupin) announced that it has received approval from Health Canada for its biosimilar Pegfilgrastim. This product will be marketed under the brand name Armlupeg and manufactured at Lupin’s Biotech facility at Pune, India.
About Pegfilgrastim
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim.
Pegfilgrastim prefilled syringes are indicated to decrease the incidence of infection, as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
Words from the MD: Lupin
Nilesh Gupta, managing director, Lupin said, “We are committed to providing affordable and high-quality treatment to our patients. The Health Canada approval for Armlupeg strengthens our ability to support Canadian patients with this mainstay treatment.”
Dr Cyrus Karkaria, president, biotech division said, “Biosimilars play an important role providing access to cancer treatment and supportive care. We are happy to receive our second biosimilar approval in Canada and look forward to maintaining this momentum with additional launches in regulated markets.”
About Armlupeg
Armlupeg (pegfilgrastim) is a biosimilar comparable to the reference biologic drug Neulasta (pegfilgrastim).
It is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
Armlupeg is available in a form of pre-filled syringe of 6mg/0.6 mL.
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets.
Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!